Allmed Medical Products Co (002950) Fair Value & Analysis
Healthcare · CN · Market cap 5.8B CNY
Analysis
Allmed Medical Products Co (002950) currently trades at ¥9.79, while our model-based Fair Value estimate is ¥12.21 — implying the stock looks roughly 24.7% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Allmed Medical Products Co.,Ltd manufactures and sells wound care and nursing material products in China. The company's traditional wound care products include non-woven and woven gauze swabs, non-adherent pads, drain sponges, abdominal pads, fluffy sponges/bandages, woven gauze and nonwoven gauze balls, eye pads, cotton-filled exodontia sponges, packing strips, ribbon gauze, cotton-tipped applicators, elastic net bandages, nose bandages, instrument covers, impregnated gauze dressings, adhesive dressings and tapes, wound bandages, kits, and precut gamgee. Its advanced wound care products consist of hydrocolloid dressings, hydrocolloid bandages, blister dressings, silicone foam dressings, superabsorbent dressings, silicone scar patches, and alginate dressings. OR consumables include x-ray woven gauze/nonwoven gauze swabs and balls, neuro and laparotomy sponges, OR towels, and disposable towel drapes. In addition, the company offers SMS fabric, sterilization wraps, surgical gowns, dra…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.